Such an outcome would be similar tothe “generics paradox” phenomenon in the pharmaceutical industry where researchers have shown that the introduction of generic drugs (which would be analogous to index funds and ETFs in our context) does not necessarily lead to the expected price drops by the branded drugs(which would be analogous to fees of active funds in our context).